Patrick Campbell

Results of a well-being study presented at ACC.21 paint a grim picture related to the impact of COVID-19 on burnout and well-being among cardiology professionals. We sat down with lead investigator Laxmi Mehta, MD, for further perspective on the issue.

A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.

An ACC.21 study assessing the risk of adverse cardiovascular and renal outcomes found a graded increase in risk across the entire glycemic spectrum, including prediabetic levels.

Hear from Muthiah Vaduganathan, MD, MPH, as he discusses the results of an analysis of data within the GWTG-HF registry that details gaps in care and management of heart failure patients with comorbid kidney disease.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

Data from the FLOWER-MI study suggest fractional flow reserve-guided PCI provided no benefit versus angiography-guided PCI for risk of death, MI, or urgent revascularization among STEMI patients with multivessel disease.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

An analysis of STOP AF First presented at ACC.21 details the quality of life improvements observed with cryoablation versus antiarrhythmic drugs as initial treatment for atrial fibrillation.

Data from post hoc analyses of REDUCE-IT indicate patients with increased on-treatment levels of EPA had a lower risk of heart failure and new hospitalization for heart failure when compared to their counterparts with the lowest on-treatment EPA levels.

Results of the LAAOS III trial provide evidence suggesting left atrial appendage occlusion could reduce risk of ischemic events by nearly a third and also reduce risk of stroke by more than 40% in patients with atrial fibrillation.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

The PARADISE-MI study missed achieving a statistically significant reduction in its primary endpoint, but offers insight into the effects of sacubitril/valsartan in patients with a history of acute MI.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

An analysis of data from more than 12k women suggests use of DXA scans can help predict women with increased risk of ASCVD events and also sheds light on the relationship between osteoporosis and cardiovascular health.

An analysis of data from more than 250k kidney transplant patients details the increased risk of mortality and graft failure according to diabetes status among these patients.

Analysis indicates women with thinning or weakened bones were at an increased risk of atherosclerotic cardiovascular disease events.

The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.

Two studies examining RCTs of herbal and dietary supplements found none of these supplements provided a clinically meaningful reduction in body weight among patients with overweight or obesity.

An analysis presented ahead of ACC.21 details the increased risk of MACE associated with prediabetes, suggesting patients were at nearly twice the risk of experiencing a major cardiovascular event.

A systematic review and meta-analysis of studies examining pediatric type 2 diabetes indicate hypertension or albuminuria was present among approximately 20% of children with type 2 diabetes.

An analysis from ACC.21 is providing an overview of the impact of prediabetes compared to normoglycemia on risk for major adverse cardiovascular disease events.

Data from an analysis of NHANES suggest nearly 1-in-5 adults with hypertension were also taking medication that may increase blood pressure.

An analysis of data from more than 12,000 women in Asia is shedding new light on the prognostic value of BMD for predicting risk of atherosclerotic cardiovascular disease in aging women.

An analysis of claims data from more than 7k patients suggests patients with severe obesity and type 2 diabetes who underwent bariatric surgery experienced a 68% reduction in cardiac mortality and 34% reduction in cardiac events compared against standard medical management.

A new study is challenging the notion that certain types of fractures, such as lower arm or wrist fractures, do not signal increased risk of subsequent fractures among postmenopausal women.

The AHA has released a scientific statement aimed at outlining the current knowledge base related to risk of cardiovascular disease associated with hormonal therapies used in the treatment of breast and prostate cancer.

New data from an analysis of the ISCHEMIA trial is providing insight into the days alive out of hospital with an initial invasive or conservative approach to the management of stable ischemic heart disease.

Data from more than 1500 general practices are providing a comprehensive overview of the impact of obesity on risk of severe COVID-19 outcomes in England—suggesting each BMI increase beyond 23 kg/m2 increased risk of hospital admission and death.